News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2018 Archives

Jun 14, 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of...

More
Jun 5, 2018

Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the upcoming Jefferies 2018 Healthcare Conference in...

More
Jun 2, 2018
Data from the Phase 1 dose-escalation and early data from the Phase 2 dose expansion phase of the ongoing PIVOT study highlighted as an oral presentation

Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced presentation of preliminary data from the ongoing PIVOT Phase 1/2 Study, which is evaluating the combination...

More
May 31, 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NKTR-181, a new molecular entity (NME) and the...

More
May 16, 2018
Abstract presentations highlight potential of NKTR-214 to be combined with multiple I-O and targeted mechanisms in the treatment of cancer

Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data will be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting, which is...

More
May 10, 2018

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2018. Cash and investments in marketable securities at March 31, 2018 were $333.8...

More
May 8, 2018

Nektar Therapeutics (NASDAQ: NKTR) today announced that it has commenced dosing patients with systemic lupus erythematosus (SLE) in a Phase 1b clinical study evaluating NKTR-358, a first-in-class...

More
May 3, 2018

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 10, 2018, after the close of U.S.-based financial markets. Howard Robin, president and...

More
Apr 30, 2018

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host an analyst and investor event with clinical investigators on Saturday, June 2, 2018 at 6:45 p.m. CDT in Chicago, IL during the...

More
Apr 24, 2018
New collaboration to explore the potential clinical benefits of two novel and complementary immuno-oncology mechanisms

Nektar Therapeutics (NASDAQ:NKTR) announced today that it has entered into a new clinical collaboration with Takeda Pharmaceutical Company Limited to evaluate Nektar's investigational medicine,...

More
Apr 15, 2018
Four Preclinical Data Presentations Showcase Nektar's Immuno-Oncology Programs, NKTR-214 and NKTR-262

Nektar Therapeutics (Nasdaq: NKTR) today announced that it is presenting new preclinical data for its immuno-oncology programs at the American Association for Cancer Research (AACR) Annual Meeting...

More
Apr 11, 2018
Combination regimen designed to engage both the body's innate and adaptive immune response to fight cancer

Nektar Therapeutics (Nasdaq: NKTR) today announced that it has initiated dosing patients in the Phase 1/2 REVEAL clinical study evaluating the efficacy and safety of the combination of...

More
Apr 3, 2018

Nektar Therapeutics (Nasdaq: NKTR) announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the previously-announced Strategic...

More
Mar 7, 2018

Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the upcoming Cowen and Company 38th Annual Health Care...

More
Mar 1, 2018

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2017. Cash and investments in marketable securities at December 31, 2017 were

More
Feb 21, 2018

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2017, on Thursday, March 1, 2018, after the close of U.S.-based financial...

More
Jan 3, 2018

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco on...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide